1/7
09:09 am
cero
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
Medium
Report
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
12/17
08:15 am
cero
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) [Yahoo! Finance]
Low
Report
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) [Yahoo! Finance]
12/17
08:00 am
cero
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
Low
Report
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
12/2
07:30 am
cero
CERo Therapeutics Announces Trading on OTCQB Market
High
Report
CERo Therapeutics Announces Trading on OTCQB Market
11/25
07:12 am
cero
Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]
Medium
Report
Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]
11/20
06:02 am
cero
CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
High
Report
CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
11/18
12:41 pm
cero
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
Low
Report
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
11/5
08:00 am
cero
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
Medium
Report
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
11/4
10:11 am
cero
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response [Yahoo! Finance]
High
Report
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response [Yahoo! Finance]
11/4
09:05 am
cero
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
High
Report
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
11/3
02:28 pm
cero
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at Maxim Group.
Medium
Report
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at Maxim Group.
11/3
08:00 am
cero
CERo Therapeutics Announces Listing on OTC Markets
High
Report
CERo Therapeutics Announces Listing on OTC Markets
10/22
08:34 am
cero
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Medium
Report
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.